Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2017 May 1;44(9):1428–1437. doi: 10.1007/s00259-017-3703-7

Fig. 3.

Fig. 3

38-year-old woman with metastatic breast cancer 10 days before (a, c, and e) and 80 days after (b, d, and f) initiation of Desatanib and Paclitaxel as first-line combination therapy showing stable disease by contrast-enhanced CT and progression by 18F-FDG PET/CT. Axial CT images before (a) and after (b) treatment initiation show stable axillary nodal metastases (arrow). Axial FDG PET/CT before (c) and after (d) treatment initiation show a marked increase in FDG avidity from SULpeak 2.1 to SULpeak 6.5. Mixed changes are seen on maximum-intensity projection PET images before (e) and after (f) treatment initiation. All nodes were stable on CT. The patient stayed on protocol as she did not meet criteria of progression by RECIST 1.1. Two months later, a new left axillary LN became palpable and the patient was switched to another treatment regimen.